Predicting Survival in Pulmonary Arterial Hypertension Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)

被引:1224
作者
Benza, Raymond L. [1 ]
Miller, Dave P. [2 ]
Gomberg-Maitland, Mardi [3 ]
Frantz, Robert P. [4 ]
Foreman, Aimee J. [2 ]
Coffey, Christopher S. [5 ]
Frost, Adaani [6 ]
Barst, Robyn J. [7 ]
Badesch, David B. [8 ]
Elliott, C. Gregory [9 ,10 ]
Liou, Theodore G. [10 ]
McGoon, Michael D. [4 ]
机构
[1] Allegheny Gen Hosp, Gerald McGinnis Cardiovasc Inst, Pittsburgh, PA 15212 USA
[2] ICON Clin Res, San Francisco, CA USA
[3] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[4] Mayo Clin, Rochester, MN USA
[5] Univ Alabama Birmingham, Birmingham, AL USA
[6] Baylor Coll Med, Houston, TX 77030 USA
[7] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA
[8] Univ Colorado, Denver, CO 80202 USA
[9] Intermt Med Ctr, Salt Lake City, UT USA
[10] Univ Utah, Salt Lake City, UT USA
关键词
prognosis; pulmonary arterial hypertension; risk factors; survival; CALCIUM-CHANNEL BLOCKERS; HEMODYNAMICS; METAANALYSIS; OUTCOMES; TRIALS; MODEL;
D O I
10.1161/CIRCULATIONAHA.109.898122
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Factors that determine survival in pulmonary arterial hypertension (PAH) drive clinical management. A quantitative survival prediction tool has not been established for research or clinical use. Methods and Results-Data from 2716 patients with PAH enrolled consecutively in the US Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) were analyzed to assess predictors of 1-year survival. We identified independent prognosticators of survival and derived a multivariable, weighted risk formula for clinical use. One-year survival from the date of enrollment was 91.0% (95% confidence interval [CI], 89.9 to 92.1). In a multivariable analysis with Cox proportional hazards, variables independently associated with increased mortality included pulmonary vascular resistance >32 Wood units (hazard ratio [HR], 4.1; 95% CI, 2.0 to 8.3), PAH associated with portal hypertension (HR, 3.6; 95% CI, 2.4 to 5.4), modified New York Heart Association/World Health Organization functional class IV (HR, 3.1; 95% CI, 2.2 to 4.4), men >60 years of age (HR, 2.2; 95% CI, 1.6 to 3.0), and family history of PAH (HR, 2.2; 95% CI, 1.2 to 4.0). Renal insufficiency, PAH associated with connective tissue disease, functional class III, mean right atrial pressure, resting systolic blood pressure and heart rate, 6-minute walk distance, brain natriuretic peptide, percent predicted carbon monoxide diffusing capacity, and pericardial effusion on echocardiogram all predicted mortality. Based on these multivariable analyses, a prognostic equation was derived and validated by bootstrapping technique. Conclusions-We identified key predictors of survival based on the patient's most recent evaluation and formulated a contemporary prognostic equation. Use of this tool may allow the individualization and optimization of therapeutic strategies. Serial follow-up and reassessment are warranted.
引用
收藏
页码:164 / U138
页数:27
相关论文
共 25 条
  • [1] Medical therapy for pulmonary arterial hypertension - Updated ACCP evidence-based clinical practice guidelines
    Badesch, David B.
    Abman, Steven H.
    Simonneau, Gerald
    Rubin, Lewis J.
    McLaughlin, Vallerie V.
    [J]. CHEST, 2007, 131 (06) : 1917 - 1928
  • [2] SURVIVAL IN PATIENTS WITH PRIMARY PULMONARY-HYPERTENSION - RESULTS FROM A NATIONAL PROSPECTIVE REGISTRY
    DALONZO, GE
    BARST, RJ
    AYRES, SM
    BERGOFSKY, EH
    BRUNDAGE, BH
    DETRE, KM
    FISHMAN, AP
    GOLDRING, RM
    GROVES, BM
    KERNIS, JT
    LEVY, PS
    PIETRA, GG
    REID, LM
    REEVES, JT
    RICH, S
    VREIM, CE
    WILLIAMS, GW
    WU, M
    [J]. ANNALS OF INTERNAL MEDICINE, 1991, 115 (05) : 343 - 349
  • [4] A meta-analysis of randomized controlled trials in pulmonary arterial hypertension
    Galie, Nazzareno
    Manes, Alessandra
    Negro, Luca
    Palazzini, Massimiliano
    Bacchi-Reggiani, Maria Letizia
    Branzi, Angelo
    [J]. EUROPEAN HEART JOURNAL, 2009, 30 (04) : 394 - 403
  • [5] Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO
  • [6] 2-4
  • [7] Pulmonary arterial hypertension in France - Results from a national registry
    Humbert, M
    Sitbon, O
    Chaouat, A
    Bertocchi, M
    Habib, G
    Gressin, V
    Yaici, A
    Weitzenblum, E
    Cordier, JFO
    Chabot, F
    Dromer, C
    Pison, C
    Reynaud-Gaubert, M
    Haloun, A
    Laurent, M
    Hachulla, E
    Simonneau, G
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 173 (09) : 1023 - 1030
  • [8] Hemodynamics and survival of patients with portopulmonary hypertension
    Kawut, SM
    Taichman, DB
    Ahya, VN
    Kaplan, S
    Archer-Chicko, CL
    Kimmel, SE
    Palevsky, HI
    [J]. LIVER TRANSPLANTATION, 2005, 11 (09) : 1107 - 1111
  • [10] Kung Hsiang-Ching, 2008, Natl Vital Stat Rep, V56, P1